Shanghai Sanyou Medical (688085) 证券之星·2025-03-26 13:14Core Viewpoint - The company has announced the use of raised funds to replace self-raised funds previously invested in projects and to cover issuance expenses, following the approval of its board and supervisory committee [1][5][6]. Fundraising Overview - The company was authorized to raise up to 214 million yuan through the issuance of shares at a price of 16.42 yuan per share, resulting in a total fundraising amount of approximately 214 million yuan, with a net amount of about 204 million yuan after deducting issuance costs [2][3]. - A special account for the management of the raised funds has been established with Shanghai Pudong Development Bank, ensuring regulatory oversight [2]. Investment and Expenditure Details - As of February 28, 2025, the actual investment amount from self-raised funds in the projects was approximately 57.22 million yuan, with 56.24 million yuan allocated for cash consideration and 975,324.54 yuan for issuance expenses [3][5]. - The total amount to be replaced by the raised funds is 57.22 million yuan, which includes both the cash consideration and issuance expenses [5]. Compliance and Approval Process - The decision to use raised funds for replacing self-raised funds was made in accordance with relevant laws and regulations, ensuring that it does not alter the intended use of the raised funds or harm the interests of shareholders [6][7]. - The supervisory committee and independent financial advisor have both provided positive opinions on the matter, confirming that the necessary procedures were followed and that the action aligns with the company's operational needs [6][7].